Jatenzo Pipeline and Next-Gen Oral Testosterone: FDA Status, Label Updates, and What Comes Next

FDA Approval History and Regulatory Path

Jatenzo earned FDA approval on March 27, 2019, under NDA 206089, making it the first oral testosterone replacement capsule cleared for use in the United States [1]. The approval was limited to adult males with conditions causing hypogonadism, such as genetic disorders, chemotherapy-related damage, or structural hypothalamic-pituitary abnormalities. The FDA explicitly excluded age-related testosterone decline from the approved indication.

This distinction matters. The agency had already issued a 2015 safety communication requiring all testosterone products to carry warnings about possible cardiovascular risk, and Jatenzo's review reflected that heightened scrutiny [2]. The Endocrine Society's 2018 clinical practice guideline recommended testosterone therapy only for men with "unequivocally low serum testosterone concentrations" paired with clinical symptoms [3]. Jatenzo's label aligns with that threshold.

Clarus Therapeutics, the original developer, had previously received a Complete Response Letter (CRL) in 2018 before the drug was ultimately approved on the second cycle. The CRL cited concerns about blood pressure increases observed in clinical trials. The final approval included a Risk Evaluation and Mitigation Strategy (REMS) program, a requirement that no other testosterone product carried at the time of Jatenzo's launch [4].

The Key Clinical Trial: Swerdloff et al. 2020

The registration trial that supported Jatenzo's approval enrolled 166 hypogonadal men in an open-label, dose-titration study over 12 months [5]. The primary endpoint was the percentage of men achieving average serum testosterone concentrations between 300 and 1 to 100 ng/dL (the eugonadal range).

Results were strong. A total of 87% of participants reached eugonadal levels by day 90. Doses were titrated from a starting point of 237 mg twice daily, with adjustments to 158 mg or 396 mg based on measured levels. The self-emulsifying lipid-based formulation (SEDDS technology) was specifically designed to enhance lymphatic absorption and bypass first-pass hepatic metabolism, a problem that had derailed earlier oral testosterone attempts.

Adverse events were consistent with testosterone class effects: increases in hematocrit, reductions in HDL cholesterol, and rises in PSA. The notable Jatenzo-specific finding was a mean systolic blood pressure increase of 3 to 5 mmHg in the treatment group. That signal drove the boxed warning and the REMS requirement [5]. Dr. Ronald Swerdloff of the Lundquist Institute noted in the publication that "the blood pressure effect is modest but requires monitoring, particularly in men with pre-existing hypertension."

Label Details and the REMS Program

Jatenzo's prescribing information contains several features that distinguish it from injectable and topical testosterone products [4]. The boxed warning reads: "Jatenzo can cause blood pressure increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death."

The Jatenzo REMS requires three components. Prescribers must be certified through the program. Pharmacies must also be certified to dispense the drug. Patients receive a medication guide explaining blood pressure monitoring requirements. Blood pressure should be checked before starting therapy and periodically after initiation.

Dosing is twice daily with food. The label specifies that fat content in meals improves absorption. Starting dose is 237 mg twice daily, with dose adjustments based on serum testosterone measured between 2 and 8 hours post-dose. The minimum dose is 158 mg twice daily, and the maximum is 396 mg twice daily.

Compared to intramuscular testosterone cypionate (which produces peak-trough fluctuations over 1 to 2 week injection intervals), Jatenzo offers more stable daily pharmacokinetics. But the twice-daily dosing requirement, combined with the food restriction, adds complexity for patients [6].

Post-Market Safety: The TRAVERSE Trial and Cardiovascular Outcomes

The TRAVERSE trial, published in the New England Journal of Medicine in June 2023, was the largest randomized cardiovascular outcomes trial ever conducted for testosterone therapy [7]. It enrolled 5,246 men aged 45 to 80 with hypogonadism and pre-existing cardiovascular disease or elevated cardiovascular risk. Participants received either 1.62% testosterone gel or placebo for a median of 33 months.

The primary composite MACE endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96 to 95% CI 0.78 to 1.17) [7]. This result was non-inferior, meaning testosterone therapy did not increase MACE risk beyond the pre-specified margin.

TRAVERSE did not study Jatenzo specifically. It used transdermal gel. The FDA has not yet removed the class-wide cardiovascular warning from testosterone labels, but the data have influenced how clinicians weigh risk. A secondary finding from TRAVERSE showed higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group, suggesting that risk monitoring remains appropriate [7].

For Jatenzo, the blood pressure signal remains the primary safety differentiator. Post-market pharmacovigilance data reported through the FDA Adverse Event Reporting System (FAERS) have not revealed new unexpected signals beyond those identified in the registration trial, though spontaneous reporting systems are inherently limited in their ability to detect rare events [2].

Tolmar Acquisition and Commercial Trajectory

Clarus Therapeutics, Jatenzo's original developer, filed for Chapter 11 bankruptcy in 2023. Tolmar Pharmaceuticals acquired the Jatenzo assets at auction. This corporate transition raised questions about the drug's commercial viability.

Several factors had constrained Jatenzo's market penetration. The REMS program created friction for prescribers and pharmacies. Pricing placed Jatenzo at a significant premium compared to generic testosterone cypionate injections (which cost as little as $30 per month). Insurance coverage remained inconsistent, with many payers requiring prior authorization and step therapy through injectables or gels first.

Tolmar has signaled interest in expanding Jatenzo's market presence, though specific pipeline extensions or label supplement filings have not been publicly disclosed as of May 2026. The American Urological Association's 2024 testosterone guideline update acknowledged oral testosterone undecanoate as a valid formulation option while emphasizing that formulation choice should consider patient preference, cost, and monitoring requirements [8].

Next-Generation Oral Androgens in Development

The oral testosterone space extends beyond Jatenzo. Several next-generation compounds are in clinical development, each attempting to address the limitations of current formulations.

Oral testosterone undecanoate generics. Jatenzo's Orange Book patents provide protection into the early 2030s, but at least two ANDA filers have indicated interest in generic versions. Patent challenges under Hatch-Waxman Paragraph IV certifications could accelerate generic entry, depending on litigation outcomes.

Dimethandrolone undecanoate (DMAU). This investigational oral androgen is being studied as both a male hormonal contraceptive and a potential TRT agent. A Phase IIb trial (NCT03452449) showed suppression of gonadotropins and maintenance of eugonadal androgen activity with once-daily dosing [9]. DMAU combines androgenic and progestogenic activity in a single molecule, which could simplify dosing compared to combination regimens.

11-beta-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC). Another dual-activity oral androgen under NIH-sponsored investigation, 11β-MNTDC demonstrated reversible suppression of spermatogenesis in a 28-day Phase I study [10]. While its primary development target is male contraception, the androgenic component could have implications for TRT formulation design.

Modified SEDDS formulations. Several pharmaceutical companies are exploring lipid-based self-emulsifying drug delivery systems that could reduce the food-effect requirement and enable once-daily dosing. These reformulation efforts aim to maintain the lymphatic absorption pathway while improving convenience.

Dr. Christina Wang of UCLA, a principal investigator in multiple male hormone trials, stated in a 2023 Endocrine Society session: "The ideal oral androgen would combine once-daily dosing, no food requirement, a clean cardiovascular profile, and predictable pharmacokinetics. We are not there yet, but the pipeline is more active than it has been in decades."

Comparing Jatenzo to Other TRT Formulations

Choosing among TRT delivery systems involves balancing efficacy, safety, convenience, and cost. Jatenzo occupies a specific niche.

Intramuscular injections (testosterone cypionate, testosterone enanthate) remain the most prescribed TRT formulations. They cost less, require no REMS, and achieve reliable testosterone levels. The trade-off is peak-trough pharmacokinetics that can produce mood and energy fluctuations, along with the need for injections every 1 to 2 weeks [6].

Transdermal gels (AndroGel, Testim, Vogelxo) offer daily application and steady-state levels. Transfer risk to partners or children is the primary concern, addressed through application site hygiene. Gels avoid the blood pressure signal seen with Jatenzo.

Nasal testosterone (Natesto) provides three-times-daily dosing with rapid absorption. It does not suppress spermatogenesis as aggressively as other formulations, making it a consideration for men interested in fertility preservation. Compliance with the three-daily schedule is the main barrier [11].

Subcutaneous testosterone pellets (Testopel) are implanted every 3 to 6 months, offering the lowest dosing frequency. Pellet extrusion and infection are uncommon but documented complications.

Jatenzo's primary advantage is oral convenience without injection or topical application. Its primary disadvantages are cost, the REMS burden, and twice-daily dosing with food.

Regulatory Outlook and Label Evolution

Several regulatory developments could affect Jatenzo's trajectory over the next 2 to 5 years.

The FDA's Bone, Reproductive and Urologic Drugs Advisory Committee has periodically revisited the cardiovascular warning language on testosterone products. If the agency determines that the TRAVERSE data support modification of the class-wide MACE warning, all testosterone labels (including Jatenzo's) could be updated. This would not remove Jatenzo's specific blood pressure boxed warning, which is based on its own trial data, but it could reduce overall prescriber hesitancy.

The REMS program itself is subject to periodic review. If real-world evidence demonstrates that the blood pressure risk is manageable with standard clinical monitoring, Tolmar could petition to modify or eliminate the REMS requirement. Removing the REMS would significantly reduce prescribing friction and could improve insurance coverage [4].

Post-market studies evaluating long-term cardiovascular outcomes specifically in Jatenzo users have not been mandated by the FDA. If Tolmar or independent investigators initiate such studies, the results could reshape the label and the drug's competitive position.

Generic competition, when it arrives, will test whether the oral testosterone category can achieve broader adoption at lower price points. The experience of generic transdermal testosterone (which drove significant market expansion for gels) suggests that affordability is a powerful driver of TRT formulation adoption.

The Endocrine Society's next guideline update, expected in 2027, will likely incorporate TRAVERSE data, oral testosterone clinical experience, and emerging pipeline agents into its recommendations. That document will influence prescribing patterns for the next decade [3].